Belite Bio Inc
Last updated September 27, 2026
Organization details
- Legal name
- Belite Bio Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Cayman Islands
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BLTE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001889109
Board of directors
-
Gary Clark Biddle · DirectorSince 2026
-
Hao-Yuan Chuang · Director · Chief Financial OfficerSince 2026
-
Ita Lu · DirectorSince 2026
-
John Michael Longo · DirectorSince 2026
-
Wan-Shan Chen · DirectorSince 2026
-
Xiao-Hui Chen · DirectorSince 2026
-
Yu-Hsin Lin · Director · Chief Executive OfficerSince 2026
Chief executives
Yu-Hsin Lin
· Chief Executive Officer
Since March 2026
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $40,542,888
- 167 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −2,200 | $194.28 | $427,414 |
| Sep 8, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,400 | $194.33 | $466,399 |
| Sep 8, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −4,120 | $195.60 | $805,889 |
| Sep 8, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −6,090 | $195.62 | $1,191,325 |
| Sep 8, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −4,475 | $196.47 | $879,200 |
| Sep 8, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −6,058 | $196.54 | $1,190,642 |
| Sep 8, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −4,605 | $197.23 | $908,244 |
| Sep 8, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −8,752 | $197.36 | $1,727,275 |
| Sep 8, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −2,562 | $198.05 | $507,392 |
| Sep 8, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,700 | $198.09 | $534,845 |
| Sep 4, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −1,633 | $180.16 | $294,201 |
| Sep 4, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,635 | $180.29 | $475,071 |
| Sep 4, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −2,000 | $181.05 | $362,107 |
| Sep 4, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,587 | $181.24 | $468,877 |
| Sep 4, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Open-market sale | −2,000 | $182.49 | $364,985 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.